Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,713JPY
7:58pm EST
Change (% chg)

¥-45 (-0.95%)
Prev Close
¥4,758
Open
¥4,760
Day's High
¥4,765
Day's Low
¥4,712
Volume
680,200
Avg. Vol
2,344,080
52-wk High
¥5,955
52-wk Low
¥4,098

Latest Key Developments (Source: Significant Developments)

Maverick and Takeda announce 5 year collaboration to advance T-cell engagement therapies
Wednesday, 11 Jan 2017 08:00am EST 

Takeda Pharmaceutical Co Ltd <4502.T> : Maverick Therapeutics and Takeda announce five-year collaboration to advance T-cell engagement therapies . Takeda invests $125 million in Maverick, including exclusive option-to-acquire .Deal provides Takeda exclusive right to purchase Maverick after five years for an undisclosed sum.  Full Article

Ariad Pharma says termination fee for Takeda deal will be $169 mln
Tuesday, 10 Jan 2017 03:17pm EST 

Ariad Pharmaceuticals Inc:If deal is terminated by co, to enter definitive agreement with respect to superior proposal, co to pay termination fee of $169 million.  Full Article

R&I affirms Takeda Pharmaceutical's rating at "AA" and announces negative outlook – R&I
Monday, 26 Dec 2016 01:27am EST 

Takeda Pharmaceutical Co Ltd <4502.T>: Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA" – R&I .Rating outlook negative– R&I.  Full Article

Tigenix submits day 120 responses to EMA for CX601 marketing authorization
Thursday, 22 Dec 2016 04:03pm EST 

Tigenix NV : Tigenix NV - Tigenix submits day 120 responses to European Medicines Agency for CX601 marketing authorization . Tigenix- expects to receive EMA day 180 list of outstanding issues in Feb 2017, anticipates decision from EMA on CX601 marketing approval during 2017 .Tigenix- if approved, would trigger the payment by Takeda to Tigenix of euro 15 million.  Full Article

Arcturus Therapeutics announces collaboration with Takeda Pharmaceuticals
Tuesday, 6 Dec 2016 12:55pm EST 

Arcturus Therapeutics : Arcturus Therapeutics announces collaboration with Takeda Pharmaceuticals to develop RNA-based therapeutics for the treatment of Nonalcoholic Steatohepatitis (NASH) .Arcturus Therapeutics- financial terms were not disclosed..  Full Article

Ultragenyx Pharma files prospectus supplement with SEC for resale of up to 352,530 shares of co's common stock held by Takeda Pharmaceutical
Friday, 2 Dec 2016 04:30pm EST 

Takeda Pharmaceutical Co Ltd <4502.T> :Ultragenyx Pharma-Filed prospectus supplement with SEC for resale of up to 352,530 shares of co's common stock held by Takeda Pharmaceutical.  Full Article

Valeant talks to sell Salix unit to Takeda for about $10 bln have broken down - CNBC, citing DJ
Wednesday, 30 Nov 2016 09:40am EST 

: Valeant talks to sell Salix unit to Takeda for about $10 bln have broken down - CNBC, citing DJ ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Takeda Pharmaceutical to raise up to T$35 mln via private placement
Thursday, 6 Oct 2016 07:12am EDT 

Takeda Pharmaceutical Co Ltd <4502.T>:Says it to issue up to 3,500,000 shares via private placement and to raise up to totally T$35 million.  Full Article

Takeda Pharmaceutical to expand into sub-Saharan Africa - Nikkei<4502.T>
Thursday, 25 Aug 2016 03:17pm EDT 

Nikkei : Takeda Pharmaceutical will expand into sub-Saharan Africa with operations set to reach full swing in next two-to-three years .  Full Article

Ultragenyx files for resale of upto 374,590 shares of co
Wednesday, 10 Aug 2016 06:05pm EDT 

Ultragenyx Pharmaceutical :Files for resale of upto 374,590 shares of co by Takeda Pharma Co ltd/its pledgees, assignees/successor-in-interest.  Full Article

BRIEF-Maverick and Takeda announce 5 year collaboration to advance T-cell engagement therapies

* Maverick Therapeutics and Takeda announce five-year collaboration to advance T-cell engagement therapies